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Abstract: BACKGROUND: Type 2 diabetes (T2D) is associated with an 
increased risk of ischaemic heart disease (IHD). An accelerated process 
of vascular ageing induced by an increased oxidative stress exposure is 
suggested as potential pathway accounting for this association. However, 
no studies have explored the relationship between markers of vascular 
ageing, measures of oxidative stress and risk of IHD in T2D.  
OBJECTIVES: To explore the association between plasma antioxidant status, 
marker of cellular ageing (leukocyte telomere length, LTL) and 10 years 
risk of IHD in patients with T2D.  
METHODS: Between 2001-2002, 489 Caucasians subjects with T2D were 
enrolled at the diabetic clinic, University College London Hospital. 
Plasma total anti-oxidant status (TAOS) and LTL were measured by 
photometric microassay and RT-PCR, respectively. The incidence of IHD 
over 10 years was determined through linkage with the national clinical 
audit of acute coronary syndrome in UK. 
RESULTS: At baseline, TAOS was associated with LTL (age adjusted: r=0.106 
p=0.024). After 10 years, 61 patients developed IHD. Lower TAOS and 
shorter LTL at baseline predicted an increased IHD risk at follow up (age 
adjusted: p=0.033 and p=0.040, respectively). These associations were 
independent of age, gender, cardiovascular risk factors, circulating 
levels of CRP and medications differences.  
CONCLUSIONS: Reduced TAOS and short LTL are interrelated pathways which 
predict risk of IHD in patients with T2D. Our findings suggest that 
antioxidant defences are important to maintain telomere integrity, 
potentially reducing the progression of vascular ageing in patients with 
T2D. 
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Several strengths contribute to the robustness of our results, including: a) the large population 
recruited in our study; b) the availability of 10 years follow up data; c) the use of outcome data 
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validation; d) the use of a well validated quantitative PCR technique to measure telomere 
length, e) the detailed phenotypic characterisation of our population which enables multiple 
adjustments and allows the independent role of many parameters to be assessed. 
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RESPONSE TO THE REVIEWER 
We thank the reviewer for his positive comments to our work. We have now revised our manuscript 
taking into account the suggestions and comments of the reviewer. We highlighted in red in the main 
manuscript and in this rebuttal the changes to our original submission. We believe that we have 
addressed all issues highlighted by the reviewer and that our manuscript has significantly improved 
and is now ready for publication. 
 
1. It is doubtful that diabetes type 1 and type 2 could be studied jointly. Although both types share 
several phenotypic features, ethiologic and pathogenic differences could make advisable to analyse 
both types separately. In this respect, adjusting the regression models by diabetes type could not be 
sufficient enough. In fact, the authors were aware of this limitation when they tried to assess the 
relations with IHD distinctly in both populations. 
We thank the reviewer for this comment. The current literature provides stronger support for a 
possible role of oxidative stress in telomere length damage and diabetes complications in subjects 
with type 2 rather than type 1 diabetes [1, 2]. Taking into account the reviewer suggestion, therefore, 
we excluded subjects with type 1 diabetes from our analyses. As reported in table 3 and 4, and figure 
1 and 2, the associations of TAOS and LTL with incidence of IHD are stronger when the analyses are 
limited to subjects with type 2 diabetes. This is the first study of this type to suggest LTL as the 
missing link which account for the known adverse impact of oxidative stress on risk of ischaemic 
heart disease in people with type 2 diabetes.  
 
2. The study outcome was the incidence of an acute coronary syndrome (referred to as IHD by the 
authors). It is unlikely that no deaths occurred over a ten-year follow-up in this high-risk population. 
So, there is a problem of competitive risks in their analysis that could result in an underestimation of 
the effect size. In this type of longitudinal studies, an event-free survival analysis is the most 
appropriate statistical approach. Logistic regression is not an adequate statistical method unless no 
deaths occurred and all the patients had approximately the same follow-up duration. Furthermore, 
it would be desirable to show all the multivariate models in detail. 
We agree that mortality data could provide even more support to our findings. Unfortunately, in the 
MINAP registry only deaths due to cardiac disease are recorded. This will not provide information on 
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However, the follow-up length was similar for all participants included in our analysis (range 9.3 to 
10.5 years). We therefore believe that logistic models are the most appropriate method to assess 
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underestimate the effect size of our associations and we have now restructured the limitation section 
of our discussion to acknowledge this potential issue.  
Page 10, line 16: “Our study has limitations which may lead to an underestimation of the strength of 
the associations between LTL and TAOS with incident IHD disease. Firstly, the primary outcome was 
IHD due to the limited information available on other atherosclerotic complications of diabetes. It is 
now well established that people with diabetes experience “silent” IHD during their lifetime. 
*Detailed Response to Reviewers
Secondly, the lack of data on non-cardiac causes of mortality precluded the opportunity to use an 
event-free survival approach in our statistical analysis. This, together with the similar follow-up 
length for all participants (range 9.3 to 10.5 years), led us to use logistic regression as preferred 
analytical models to explore the associations between TAOS and LTL with IHD. Thirdly, we could not 
perform measures of intracellular antioxidants. TAOS provides an estimation of total antioxidant 
capacity, which in turn is dependent on the contributions of albumin, bilirubin and urate. We cannot 
exclude therefore that measures of intracellular oxidative stress or the assessment of additional 
extracellular antioxidants could provide better estimation of the influence of antioxidant capacities 
on LTL and risk of future cardiovascular events. These factors do not attenuate, however, the 
importance of the biological associations emerging from our data. Larger epidemiological studies 
with multiple measures of LTL will be necessary to provide a more accurate estimation of the 
associations between TAOS, LTL and IHD.” 
In addition, we have now showed details of all multivariable models in table 3. 
 
3. Given that inflammation plays an important role in the pathogenic consequences in diabetic 
patients, the relationship between markers of inflammation (CRP) and telomere length should be 
addressed. The inclusion of CRP in the multivariate models could be very informative as well. 
We thank the reviewer for this important observation. We now added CRP to our multivariate models 
(model 3). While we found that people with higher CRP tended to have shorter LTL, as expected 
(table 1 of the main manuscript), addition of CRP to our fully adjusted model did not affect our results 
(table 4 of the main manuscript).  
Taking into account these new results, we emended our discussion and added the following 
sentences: 
Page 10, line 4: “For example, while people with lower TAOS had higher HbA1c and triglycerides with 
lower HDL-cholesterol, adjustment for these cardiovascular risk factors did not attenuate the 
association between TAOS and IHD. Similarly, higher CRP tended to be associated with shorter LTL, as 
expected, but addition of CRP to our fully adjusted model did not affect our results.”  
 
4. The authors use the generic variable "BP lowering" to include all the antihypertensive drugs. Was 
a specific effect of ACEi/ARBs or CCB explored? 
We thank the reviewer for this suggestion. We analysed the impact of different antihypertensive 
medications on the association between LTL or TAOS and incidence of IHD. As reported in table 1S 
and 2S of the supplementary data, we did not find any specific effect of the different subclass of 
antihypertensive medications on the association between TAOS or LTL with IHD. In the results 
section, the following sentence was added to reflect these new analyses:   
Page 8, line 11: “Adjustment for medication use as well as for different classes of anti-hypertensives 
did not materially affect the association between TAOS and IHD, nor the association between LTL and 
IHD (Table 1S and 2S of Supplementary Material).” 
5. Abstract. In the Conclusion section, the authors state "Treatments which increase antioxidant 
capacity and prevent telomere damage may reduce the risk of IHD in diabetes". This is speculative 
and cannot be concluded from the results of the study. 
We accept the point being made by the referee. Taking into account the suggestion of the reviewer, 
we now changed the last sentence of the abstract as follow: 
Page 2, line 20: “Our findings suggest that antioxidant defences are important to maintain telomere 
integrity, potentially reducing the progression of vascular ageing in patients with T2D.” 
 
6. Reference # 13. The author's name is misspelled. 
We apologise for this misspelling, which has now been corrected. 
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ABSTRACT (Words=240) 
BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of ischaemic heart 
disease (IHD). An accelerated process of vascular ageing induced by an increased oxidative 
stress exposure is suggested as potential pathway accounting for this association. However, no 
studies have explored the relationship between markers of vascular ageing, measures of 
oxidative stress and risk of IHD in T2D.  
OBJECTIVES: To explore the association between plasma antioxidant status, marker of cellular 
ageing (leukocyte telomere length, LTL) and 10 years risk of IHD in patients with T2D.  
METHODS: Between 2001-2002, 489 Caucasians subjects with T2D were enrolled at the 
diabetic clinic, University College London Hospital. Plasma total anti-oxidant status (TAOS) and 
LTL were measured by photometric microassay and RT-PCR, respectively. The incidence of IHD 
over 10 years was determined through linkage with the national clinical audit of acute coronary 
syndrome in UK. 
RESULTS: At baseline, TAOS was associated with LTL (age adjusted: r=0.106 p=0.024). After 10 
years, 61 patients developed IHD. Lower TAOS and shorter LTL at baseline predicted an 
increased IHD risk at follow up (age adjusted: p=0.033 and p=0.040, respectively). These 
associations were independent of age, gender, cardiovascular risk factors, circulating levels of 
CRP and medications differences.  
CONCLUSIONS: Reduced TAOS and short LTL are interrelated pathways which predict risk of 
IHD in patients with T2D. Our findings suggest that antioxidant defences are important to maintain 
telomere integrity, potentially reducing the progression of vascular ageing in patients with T2D. 
 
Key words: Diabetes, cardiovascular risk, oxidative stress, telomeres  
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INTRODUCTION 
Type 2 diabetes mellitus (T2D) is a chronic disease characterized by multiple metabolic 
derangements, which disrupt the balance between reactive oxygen species and antioxidant 
defences at the cellular level [1]. Antioxidant capacity of plasma is the primary measure and 
marker to evaluate the status and potential of oxidative stress in the body. Plasma contains 
many compounds, which function against the oxidative stressors in the body thus protecting 
the cell and cellular biomolecules from being damaged. The reduced antioxidant capacity 
described in patients with diabetes results in greater exposure to oxidative stress and 
subsequent damage to proteins, lipids, and DNA, which leads to a rapid deterioration of a 
broad range of cellular functions and premature cellular ageing [2,3]. These mechanisms 
underpin the development of several diabetic complications, including ischaemic heart disease 
(IHD)[4]. T2D can therefore be regarded as a model of accelerated biological ageing due to 
increased levels of oxidative stress exposure, and the increased risk of IHD as a manifestation of 
premature vascular ageing [5].  
Over the last ten years, epidemiological studies have suggested that peripheral blood 
leukocyte telomere length (LTL) can be a useful biomarker of cardiovascular ageing. Multiple 
reports [6-9], including a recent meta-analysis and GWAS study [10,11], suggested that LTL are 
on the causal pathways for IHD. The association between LTL and IHD is thought to be 
mediated by oxidative stress exposure which is currently considered to be an important driver 
of atherosclerosis and its complications [12] as well as to cause a faster LTL attrition [13]. 
However, the impact of a reduced antioxidant capacity on LTL and risk of IHD has not been 
explored in patients with T2D. 
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We have studied a well characterised cohort of patients with T2D in order to explore the 
relationship between a baseline measure of total serum antioxidant capacity and LTL with 
subsequent risk of IHD over 10 years. 
METHODS 
Study sample 
The University College Diabetes and Cardiovascular disease (UDAC) study comprises 1011 
individuals, who were recruited consecutively from the diabetes clinic at UCL Hospitals in 2001–
2. The study was designed to investigate the association between inflammatory/metabolic 
genes and biochemical risk factors implicated in IHD in patients with diabetes. The study has 
been described in detail elsewhere [14,15]. All patients had type 1 or type 2 diabetes according 
to WHO criteria [16]. Anthropometric measures (height, weight and BMI), blood pressure and 
blood samples as well as information on smoking history and current medication use were 
collected during their routine diabetes clinic appointment. Our analysis focusses on the 
subgroup of individuals of individuals with a diagnosis of T2D, of Caucasian origin and with 
available measures of plasma total anti-oxidant status (TAOS), LTL and cardiovascular outcome 
(n=489, Figure 1S of Supplementary Material). The rationale for the restriction of the analysis to 
the T2D and Caucasian groups was to reduce the heterogeneity of our study sample, due to the 
known differences in the pathogenesis of cardiovascular complication between different types 
of diabetes [17] and the different LTL distribution and rate of attrition amongst ethnic groups 
[18,19]. Further, despite multiple studies documented that LTL can predict the risk of IHD in 
White American and Caucasian populations, there are no reports as of yet on South Asian 
populations with or without diabetes. Ethical approval was granted by UCL/UCLH Ethics 
Committee and all subjects gave written informed consent. 
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Plasma total anti-oxidant status and cardiovascular risk factors assays 
Plasma samples were collected within the 12-months recruitment period and stored 
immediately at −80 °C. Plasma total anti-oxidant status (TAOS) was measured by Sampson’s 
modification of Laight’s photometric microassay [20], using 2.5μl citrated plasma samples in 96-
well ELISA plates. TAOS was selected as: a) it correlates with markers of oxidative damage in 
peripheral blood of patient with diabetes [20,21]; b) there is already evidence supporting a 
different anti-oxidant status of patients with type 1 or type 2 diabetes when compared to 
healthy controls [22,23]; c) it is associated with subclinical atherosclerosis coronary artery 
disease events in observational and longitudinal studies including patients with and without 
diabetes [21,24]. Inter- and intra-assay coefficients of variation were 14.1% and 4.3%, 
respectively. Levels of total cholesterol, triglycerides, HDL cholesterol and HbA1c were assayed 
according to standard chemistry protocols [25]. LDL cholesterol was calculated by the Friedwald 
equation. 
 
DNA extraction and LTL assay 
Leukocyte DNA was extracted by the salting-out method [26]. Telomere length was measured 
using a validated quantitative PCR-based method as previously described [27]. Briefly, the 
relative telomere length was calculated as the ratio of telomere repeats to single-copy gene 
(SCG) copies (T/S ratio). For each sample the quantity of telomere repeats and the quantity of 
SCG copies were determined in comparison to a reference sample in a telomere and a SCG 
quantitative PCR, respectively. The raw data from each PCR was analysed using the 
comparative quantification analysis (Rotor-Gene 6000 software, Corbett Research Ltd., 
Cambridge, UK). All PCRs were performed on the Rotor-Gene 6000 (Corbett Research Ltd., 
Cambridge, UK). The coefficient of variation in repeated measurements was 5.6%.  
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Coronary heart disease data 
Data on incident IHD disease was retrieved from the Myocardial Ischaemia National Audit 
Project (MINAP), held within the National Institute of Cardiovascular Outcome and Research 
(NICOR). This is a national registry of patients admitted to hospitals in England and Wales with 
acute coronary syndromes (ACS). It was established in 1998 to provide participating hospitals 
with a common mechanism for auditing performance against standards defined in the National 
Service Framework for Coronary Heart Disease [28]. Data collection began in October 2000 and 
by mid-2002 all acute hospitals in England and Wales were participating in the registry. The 
characteristics, organization, availability, data quality, validation and accessibility of 
cardiovascular outcome data contained in the MINAP have been previously described [29]. A 
new diagnosis of IHD disease was identified using hospital discharge records, markers of 
myocardial necrosis, results of coronary angiograms and coded electrocardiographic findings, in 
accordance with the internationally agreed definition of ST-segment elevation myocardial 
infarction (STEMI) [30] and acute coronary syndrome without persistent ST-segment elevation 
[30-32].  
 
Statistical analysis 
Mean values between groups were compared using two sample t-tests. Normality was tested 
using the Shapiro-Wilk test. Variables were log-transformed where necessary to normalise the 
distribution and geometric means and approximated standard deviations are reported for these 
variables with t-tests performed on the log-transformed data. Where the data could not be 
normalised, medians and interquartile ranges are presented and differences were tested using 
the Mann-Whitney U test. For categorical variables, chi-squared tests were used. Association 
between continuous variables was assessed by Spearman rank correlation. Adjustment was 
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made for covariates by including them as terms in regression or logistic regression models. 
Particularly, a series of multivariable regression models were fitted to examine whether 
traditional CV risk factors and other potential confounders influenced the association observed 
between LTL and the risk of IHD disease. Results from three multiple regression models are 
reported: model 1 = Age adjusted; Model 2 = Model 1 + adjustments for sex, HbA1c and 
smoking; Model 3 = Model 2 + adjustments for total cholesterol, blood pressure, C-reactive 
protein (CRP) and medications. Additionally, we explored whether further adjustment of model 
2 for specific classes of anti-hypertensive medications (angiotensin converting enzyme, 
angiotensin receptor blockers or calcium channel blockers) had an impact on the association of 
TAOS or LTL with IHD. The α value for statistical significance for associations was set at 0.05. 
Analyses were performed with STATA version 13.  
 
RESULTS 
Baseline characteristics 
At baseline, the patients studied were overweight, exhibited suboptimal gluco-metabolic 
control, and relatively high levels of blood pressure (Table 1). The average TAOS was 44.8% 
[36.5-53.3] and it was higher in people with longer LTL (unadjusted: r=0.093, p=0.046; age 
adjusted: r=0.106, p=0.024) and higher levels of HDL-cholesterol, while it was reduced in 
patients with elevated glucose, HbA1c and triglycerides levels (table 1). Furthermore, LTL was 
inversely associated with age (r=-0.150; p=0.002), while there were no differences based on 
gender or cigarettes smoking distribution, nor was LTL associated with traditional 
cardiovascular risk factors including BMI, total cholesterol, HDL-cholesterol, systolic and 
diastolic blood pressure and HbA1c. Subjects with shorter LTL tended to have elevated levels of 
circulating CRP (Table 1). 
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Cardiovascular outcomes 
After 10 years, 61 patients (12.5%) developed IHD disease. Patients with IHD had higher 
baseline BMI and CRP but lower levels of HDL-cholesterol compared to those in the non-
ischaemic group (Table 2). Notably, the IHD disease group had lower baseline TAOS compared 
to the non-ischaemic group (unadjusted: p=0.033; adjusted for age: p=0.016) (Figure 1). This 
association was not affected by adjustments included in model 2 (p=0.028) and remained 
significant in the fully adjusted model (p=0.022) (Table 3). Similarly, age-adjusted LTL was 
shorter in the IHD disease group compared to the non-ischaemic group (unadjusted: p=0.040; 
adjusted for age: p=0.039) (Figure 2). This difference was not affected by adjustments included 
in model 2 (p=0.034) and remained significant in the fully adjusted model (model 3, p=0.020) 
(Table 4). Adjustment for medication use as well as for different classes of anti-hypertensives 
did not materially affect the association between TAOS and IHD, nor the association between 
LTL and IHD (Table 1S and 2S of Supplementary Material). 
 
DISCUSSION 
This is the first study to explore the association between LTL, antioxidant capacity and 
subsequent risk of IHD disease in patients with T2D. We showed that baseline LTL was inversely 
related to TAOS and that shorter LTL and lower TOAS at baseline predicted IHD disease risk over 
10 years, independently from traditional cardiovascular risk factors. This suggests that a 
reduced antioxidant capacity increases the risk of IHD in patients with T2D, potentially 
accelerating the vascular ageing process by damaging telomere sequences.  
Previous reports have described associations between LTL and incidence of IHD in 
healthy populations [6-8]. In T2D, only observational studies have reported associations 
between LTL and prevalence of diabetes complications [33]. We now show that LTL can predict 
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future incidence of IHD disease in prospective follow up over 10 years. This is likely to be due to 
the unique ability of LTL to reflect an individual’s cumulative exposure to inflammation and 
oxidative stress. Indeed, it is now well established that oxidative stress exposure increases LTL 
shortening and contributes to the initiation and progression of atherosclerosis. A higher 
oxidative stress exposure results in LDL oxidation, vascular inflammation and increased 
vulnerability of atherosclerotic plaques to rupture [12]. Similarly, oxidative stress exerts a major 
influence on telomere dynamics for two principal mechanisms. Firstly, the GGG triplets on the 
telomere sequence are highly sensitive to the hydroxyl radical [13]. Thus, conditions 
characterised by increased levels of oxidative stress exposure, such as T2D, can result in a 
longer stretch of telomeres being lost with each cell replication [13]. This has previously been 
confirmed by Sampson et al., who documented an association between oxidative DNA damage 
and monocyte telomere length in patients with T2D [34]. Secondly, in contrast to genomic DNA, 
telomeric DNA was reported to be deficient in the repair of single-strand breaks [35]. As a 
result, telomeres appear to be especially vulnerable to the accumulation of ROS-induced DNA-
strand breaks [36].  
We found an increased risk of IHD disease in T2D patients with reduced antioxidant 
capacity. A decreased antioxidant capacity is associated with an increase in oxidative stress 
which is thought to be on the causal pathway for diabetic vascular complications. Our study 
supports this hypothesis by demonstrating an inverse relationship of TAOS with risk of IHD 
disease risk. In line with our findings, Broedbaek et al. recently showed that higher urinary 
markers of nucleic acid oxidation are associated with increased mortality in newly diagnosed 
patients with T2D [37]. Despite this, the majority of clinical trials of antioxidants have failed to 
show significant improvement in CV outcomes in patients with diabetes [38,39]. This may be 
due to the inability of exogenously provided compounds (like antioxidant vitamins) to reach 
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intracellular compartments and prevent oxidative damage to key proteins, lipids and nucleic 
acids [40].  
The association between TAOS and LTL with incident IHD disease was independent of 
traditional cardiovascular risk factors. For example, while people with lower TAOS had higher 
HbA1c and triglycerides with lower HDL-cholesterol, adjustment for these cardiovascular risk 
factors did not attenuate the association between TAOS and IHD. Similarly, higher CRP tended 
to be associated with shorter LTL, as expected [41-43], but addition of CRP to our fully adjusted 
model did not affect our results. This finding could be partially due to comparable 
cardiovascular risk factors burden between groups included in this study. Indeed LDL 
cholesterol levels were similar between the ischaemic and control groups, although use of 
statin was more prevalent in the former. This observation suggests that, whilst optimal 
treatment could normalize cardiovascular risk factors of people with T2D, this might not restore 
the antioxidant defences and counteract their impact on the cellular aging process. This 
hypothetical mechanism could explain the increased residual risk of cardiovascular events 
observed in people with T2D despite the improved cardiovascular risk factor burden. 
Our study has limitations, which may lead to an underestimation of the strength of the 
associations between LTL and TAOS with incident IHD disease. Firstly, the primary outcome was 
IHD due to the limited information available on other atherosclerotic complications of diabetes. 
It is now well established that people with diabetes experience “silent” IHD during their 
lifetime. Secondly, the lack of data on non-cardiac causes of mortality precluded the 
opportunity to use an event-free survival approach in our statistical analysis. This, together with 
the similar follow-up length for all participants (range 9.3 to 10.5 years), led us to use logistic 
regression as preferred analytical models to explore the associations between TAOS and LTL 
with IHD. Thirdly, we could not perform measures of intracellular antioxidants. TAOS provides 
11 
 
an estimation of total antioxidant capacity, which in turn is dependent on the contributions of 
albumin, bilirubin and urate. We cannot exclude therefore that measures of intracellular 
oxidative stress or the assessment of additional extracellular antioxidants could provide better 
estimation of the influence of antioxidant capacities on LTL and risk of future cardiovascular 
events. These factors do not attenuate, however, the importance of the biological associations 
emerging from our data. Larger epidemiological studies with multiple measures of LTL and 
oxidative stress will be necessary to provide a more accurate estimation of the associations 
between TAOS, LTL and IHD.  
 
Conclusions 
A single measure of antioxidant capacity and LTL predicted 10 years IHD risk in patients 
with diabetes. This association is likely to depend upon an increased damage of the telomere 
sequence in people with diabetes and suggests that a process of early vascular ageing induced 
by oxidative stress contributes to increase cardiovascular morbidity and mortality in diabetes. 
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Legends 
Figure 1. Box plot showing difference of TAOS at baseline between ischaemic and non-
ischaemic groups (median and IQR); P=0.033. 
Figure 2. Box plot showing difference of LTL at baseline between ischaemic and non-ischaemic 
groups; analysis adjusted for age; P= 0.040. 
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Table 1. Baseline characteristics of the study sample and their associations with TAOS and 
LTL.  
Characteristics N=489 
Association with 
TAOS 
Association with LTL 
r p r p 
Age, years e 
Smoking, % c 
BMI, Kg/m2 b 
SBP§, mmHg b 
DBP§, mmHg b 
Total cholesterol, mmol/L a 
LDL, mmol/L a 
HDL, mmol/L b 
Triglyceride, mmol/L b 
CRP, mg/L b 
Glucose, mmol/L b 
Hba1c, % (mmol/mol) b 
TAOS, % d 
Age adjusted LTL, T/S ratiob 
Statin treatment, % c 
BP lowering, % c 
67  [24-91] 
77 (16%) 
29.4 ± 5.6 
141 ± 19 
79 ± 11 
5.15 ± 1.06 
2.79 ± 0.92 
1.29 ± 0.37 
1.93 ± 1.09 
1.76 ± 1.51 
10.00 ± 4.31 
7.66 ± 1.64 
44.8 [36.5-53.3] 
0.97 ± 0.21 
124 (26%) 
316 (65%) 
0.078 
-0.0007 
-0.058 
0.075 
0.067 
-0.035 
0.023 
0.132 
-0.178 
0.074 
-0.164 
-0.100 
- 
0.106 
-0.010 
-0.0007 
0.089 
0.987 
0.204 
0.104 
0.145 
0.450 
0.625 
0.004 
0.0001 
0.106 
0.0003 
0.030 
- 
0.024 
0.833 
0.987 
-0.150  
-0.019 
-0.0025 
0.061 
-0.034 
0.040 
0.068 
-0.003 
-0.055 
-0.092 
-0.054 
0.011 
0.106 
- 
0.022 
-0.013 
0.002 
0.685 
0.957 
0.192 
0.473 
0.396 
0.149 
0.942 
0.239 
0.051 
0.251 
0.817 
0.024 
- 
0.646 
0.785 
Data expressed as: a) mean ± Standard deviation for normally distributed variables, b) 
geometric mean ± approximate standard deviation for log-normally distributed variables, c) N 
(percentage) for binary variables or d) median [interquartile range] for not normally distributed 
variables. e) Age is show as median [range]. §SBP: Systolic blood pressure; DBP: diastolic blood 
pressure. Apart from the association with age, all other associations with LTL were adjusted for 
age. 
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Table 2. Baseline differences between ischaemic and non-ischaemic groups 
Characteristics Non-ischaemic  
N=428 
Ischaemic 
N=61 
P value 
 
Age, years e 
Smoking, % c 
BMI, Kg/m2 b 
SBP§, mmHg b 
DBP§, mmHg b 
Total cholesterol, mmol/L a 
LDL, mmol/L a 
HDL, mmol/L b 
Triglyceride, mmol/L b 
CRP, mg/L b 
Glucose, mmol/L b 
Hba1c, % (mmol/mol) b 
TAOS, % d 
Age adjusted LTL, T/S ratiob 
Statin treatment, % c 
BP lowering, % c 
66[24-91] 
70 (17%) 
29·1 ± 5.6 
142 ± 18 
79 ± 11 
5.18 ± 1.08 
2.80 ± 0.93 
1.30 ± 0.38 
1.90 ± 1.08 
1.70 ± 1.46 
9.94 ± 4.33 
7.67 (60) ± 1.67 
44.5 [36.9-53.3] 
0.98 ± 0.21 
94 (22%) 
268 (63%) 
67 [44-84] 
7 (12%) 
30.9 ± 5.8 
140 ± 23 
76 ± 10 
4.94 ± 0.97 
2.69 ± 0.90 
1.17 ± 0.29 
2.17 ± 1.08 
2.17 ± 1.90 
10.38 ± 4.15 
7.63 (60) ± 1.43 
40.5 [32.3-47.8] 
0.92 ± 0.18 
30 (50%) 
48 (79%) 
0.725 
0.344 
0.026 
0.444 
0.037 
0.094 
0.353 
0.004 
0.087 
0.041 
0.471 
0.865 
0.033 
0.040 
<0.001 
0.019 
Data expressed as: a) mean ± Standard deviation for normally distributed variables, b) 
geometric mean ± approximate standard deviation for log-normally distributed variables, c) N 
(percentage) for binary variables or d) median [interquartile range] for not normally distributed 
variables. e) Age is show as median [range]. §SBP: Systolic blood pressure; DBP: diastolic blood 
pressure. Differences between ischaemic and non-ischaemic groups were assessed using 
unpaired t-test for normally or log-normally distributed variables. Where the data could not be 
normalised, medians and interquartile ranges are presented and differences were tested using 
the Mann-Whitney U test. χ2 tests were used for categorical variables. 
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Table 3. Multivariable models assessing differences of TAOS between non-ischaemic and 
ischaemic heart disease groups. 
 
Models Variables Logistic regression 
OR* (95% CI) P values 
Model 1 Age (1 year increase) 
TAOS (1 quintile increase) 
1.01 (0.98-1.03) 
0.78 (0.64-0.95) 
0.537 
0.016 
Model 2 Age (1 year increase) 
Sex (Female: Male) 
Hba1c (1 SD increase) 
smoking (current vs. non) 
TAOS (1 quintile increase) 
1.01 (0.98-1.03) 
0.61 (0.34-1.11) 
1.04 (0.78-1.38) 
0.67 (0.29-1.57) 
0.80 (0.65-0.98) 
0.555 
0.104 
0.788 
0.361 
0.028 
Model 3 Age (1 year increase) 
Sex (Female: Male) 
Hba1c (1 SD increase) 
smoking (current vs. non) 
SBP (1 SD increase) 
DBP (1 SD increase) 
Blood pressure medications 
Lipid lowering medications 
CRP (1 SD increase) 
TAOS (1 quintile increase) 
1.00 (0.97-1.03) 
0.45 (0.23-0.86) 
0.98 (0.71-1.34) 
0.73 (0.30-1.78) 
1.13 (0.76-1.68) 
0.64 (0.43-0.96) 
1.58 (0.79-3.19) 
3.29 (1.77-6.11) 
1.48 (1.09-2.03) 
0.78 (0.63-0.96) 
0.880 
0.017 
0.984 
0.494 
0.552 
0.030 
0.197 
0.0002 
0.013 
0.022 
*Odds ratio for a unit increase of the independent variable 
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Table 4. Multivariable models assessing differences of LTL between non-ischaemic and 
ischaemic heart disease groups. 
Models Variables Logistic regression 
OR* (95% CI) P values 
Model 1 Age (1 year increase) 
T/S ratio (1 SD increase) 
1.00 (0.98-1.03) 
0.74 (0.55-0.99) 
0.816 
0.039 
Model 2 Age (1 year increase) 
Sex (Female: Male) 
Hba1c (1 SD increase) 
smoking (current vs. non) 
T/S ratio (1 SD increase) 
1.00 (0.98-1.03) 
0.56 (0.31-1.04) 
1.02 (0.77-1.35) 
0.59 (0.24-1.45) 
0.72 (0.53-0.97) 
0.819 
0.067 
0.880 
0.248 
0.034 
Model 3 Age (1 year increase) 
Sex (Female: Male) 
Hba1c (1 SD increase) 
smoking (current vs. non) 
SBP (1 SD increase) 
DBP (1 SD increase) 
Blood pressure medications 
Lipid lowering medications 
CRP (1 SD increase) 
T/S ratio (1 SD increase) 
0.99 (0.96-1.03) 
0.42 (0.21-0.83) 
1.00(0.72-1.39) 
0.72 (0.28-1.85) 
1.09 (0.72-1.64) 
0.67 (0.43-1.02) 
1.73 (0.82-3.62) 
3.83 (2.02-7.25) 
1.29 (0.94-1.78) 
0.69 (0.50-0.94) 
0.705 
0.013 
0.984 
0.497 
0.681 
0.062 
0.148 
0.00004 
0.121 
0.020 
*Odds ratio for a unit increase of the independent variable 
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Figure 2 
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